期刊文献+

急性红白血病的生物学特点及初步疗效的临床分析

Biological characteristics and primary therapeutic response of acute erythroid leukemia
原文传递
导出
摘要 目的 探讨急性红白血病(AEL)的生物学特点,并对初步治疗的疗效进行分析.方法 回顾分析28例初治AEL患者的临床资料,其中伴多系病态造血及无多系病态造血患者各14例,针对其形态学、免疫学、细胞遗传学和分子生物学特征及初次诱导治疗完全缓解(CR)率进行分析.结果 28例初治AEL患者中有14例(50%)伴多系病态造血,累及二系或三系;6例行免疫分型检测,高表达髓系原始细胞相关抗原;8例行染色体核型分析,5例核型异常,其中4例为复杂核型,1例伴有+8染色体;4例行WT1分子检测均为阳性;诱导治疗CR率为39.29%(11/28),伴多系病态造血组为35.71%(5/14),无多系病态造血组为42.86%(6/14),两组间差异无统计学意义(P>0.05).复杂核型组为25.00%(1/4),预后中等核型组为50.00%(2/4).结论 AEL具有独特的生物学特征:伴有较高的多系病态造血发生率;异常核型检出率高,且多为累及5号和(或)7号染色体的复杂核型,复杂核型组CR率低;对化疗CR低,治疗效果差. Objective To observe the biological characteristics and analyse primary therapeutic response of acute erythroid leukemia.Methods The data of 28 patients primarily diagnosed as acute erythroid leukemia were analyzed.The patients were divided into with muhilineage dysplasia group and without muhilineage dysplasia group,and the morphology,immunology,cytogenetics and molecular biology characteristics and the complete remission rate of the first induction therapy were compared.Results There were 14 cases(50%)with muhilineage dysplasia,which involved in two lineage or trilineage.In 6 cases by flow cytometry,the myeloid blast immunophenotypes were common expressed.In 8 cases detected by karyotype analysis,5 cases were chromosomal abnormal,including 4 cases were complex chromosomal abnormal,1 case was trisomy 8.In 4 cases underwent WT1 detection,all of them were positive.The complete remission rate of the first induction therapy was 39.29%(11/28),the ratein the multilineage dysplasia group was 35.71%(5/14),and the ratein without multilineage dysplasia group was 42.86%(6/14),the difference had no statistical significance(P>0.05).The complete remission rate of the complex chromosome group was 25.00%(1/4),the intermediate prognostic group was 50.00%(2/4).Conclusions Acute erythroid leukemia had special biological features different from other subtype AML:accompanyed with high frequency of multilineage dysplasia.The abnormality of karyotype were high,and it was often complex karyotype involved with chromosome 5 and/or chromosome 7,which had a low complete remission rate.The complete remission rate of chemotherapy was low,treatment effect was poor.
作者 施杰 李艳
出处 《白血病.淋巴瘤》 CAS 2013年第10期607-611,共5页 Journal of Leukemia & Lymphoma
关键词 白血病 幼红细胞 急性 伴多系病态造血 染色体核型 疗效 Leukemia,erythroblastic,acute With multilineage dysplasia Karyotype Therapeutic response
  • 相关文献

参考文献23

  • 1Brito-Babopulle F, Catovsky D, Galton DA, et al. Clinical and laboralory features of de novo acute myeloid leukemia with trilineage myelodysplasia. Br J Haemalol, 1987, 66: 445-450.
  • 2Goasguen JE, Matsuo T, Cox C, et al. Evaluation o f the dysmyelopiesis in 336 patients with de novo acute myeloid leukemia, major importance of dysgTanulopoiesis for remisson and survival. Leukemia, 1992, 6: 520-525.
  • 3张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2008:220-227.
  • 4Arber DA, Bnning RD, Orazi A, et al. Acute myeloid leukemia, not otherwise specified//Swerdlow S, Campo E, Harris N, Jaffe E, et al. WHO classification of turnouts of haematopoietic and lymphoid tissue, 4th ed. Lyon: IARC Press. 2008.
  • 5Domingo-Claros A, Larriba I,Rozman M, et al. Acute erythroid neoplastic proliferations. A biological study based on 62 patients. Haematoloica, 2002, 87: 148-153.
  • 6张文荟,雷平冲,张茵,马保根,孙恺,王臻.原发性骨髓纤维化转急性髓系白血病M6一例并文献复习[J].白血病.淋巴瘤,2013,22(3):176-178. 被引量:1
  • 7Bene MC, Castoldi G, Knapp W, et al. Propasals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 1995, 9: 1783-1786.
  • 8Kasyan A, Medeiros LJ, Zuo Z, et al. Acute erythroid leukemia as defined in the World Health Organization classificalion is a rare and pathogenetically heterogeneous disease. Mod Pathol, 2010, 23:1113- 1126.
  • 9Kuchenbauer F, Kern W, Schoch C, et al. Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica, 2005, 90: 1617-1625.
  • 10Hasserjian lip, Zuo Z, Garcia C, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO Classification. Blood, 2010, 115: 1985-1992.

二级参考文献18

  • 1陆滢,金洁,徐伟来.WT1基因在骨髓增生异常综合征及急性白血病患者中的表达[J].中国实验血液学杂志,2004,12(4):464-466. 被引量:7
  • 2Wang Z Y,Qiu Q Q,Deuel T F.The Wilms tumor gene product WT1activates or supresses transcription through separate functional domains[J].J Biol Chem,1993,268(13):9172-9175.
  • 3Phelan S A,Lindberg C,Call K M,et al.Wilms tumor gene WT1 mRNA is down regulated during induction of erythroid and megakaryocytic differentiation of K562 cells [J].Cell Growth Differ,1994,5(6):677-686.
  • 4Sekiya M,Adachi M,Hinoda Y,et al.Downregulation of Wilms tumor gene (WT1) during myelomoonocytic differentiation in HL-60 cells[J].Blood,1994,83(7):1876-1882.
  • 5Inoue K,Sugiyama H,Nakagawa M,et al.WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia[J].Blood,1994,84(10):3071-3079.
  • 6Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood, 2005, 105: 973-977.
  • 7Garcia S, Miguel A, Miguel A, et al. Idiopathic myelofibrosis terminating in erythroleukemia. Am J Hematol, 1989, 32: 70-71.
  • 8Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work. Curt Hematol Malig Rep, 2012, 7: 78-86.
  • 9Tiedt R, Hao-shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood, 2008, 111: 3931-3940.
  • 10Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts intransformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutalion. Blood, 2007, 110: 375-379.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部